Marker Therapeutics today announced that updated clinical data from an investigator-sponsored Phase 1/2 trial led by Baylor College of Medicine were selected for oral presentation during a plenary session at the upcoming American Association for Cancer Research’s (AACR) Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy conference.
Marker Therapeutics will present at and participate in two upcoming investor conferences.
Marker Therapeutics reports Q1 earnings.
President and Chief Executive Officer, Peter L. Hoang, to present at the 2019 Bank of America Merrill Lynch Health Care Conference.
Company to host business update call and webcast today at 5:00 p.m. EDT
Marker Therapeutics announces business update conference call and webcast on Thursday, March 28th.
Marker Therapeutics announces updated data from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies.
Marker Therapeutics would like to congratulate Scientific Advisory Board Member, Helen E. Heslop, MD, DSc (Hon), on receiving the ASBMT Lifetime Achievement Award.
President and CEO, Peter L. Hoang, and Chief Development Officer, Dr. Juan Vera, will be presenting at the CAR-TCR Summit Europe.
Marker Therapeutics has formally relocated their corporate headquarters from Jacksonville, Florida to Houston, Texas. In addition, the Company has announced that it is now a resident company at Johnson & Johnson Innovation – JLABS (JLABS at TMC).